| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2851688 | American Heart Journal | 2006 | 8 Pages |
Abstract
In a population of patients with health insurance and prescription drug coverage, adherence to β-blocker therapy in the first year after myocardial infarction is poor, indicating that factors other than medication cost are important determinants of long-term adherence. Quality improvement initiatives focused on long-term adherence are needed to realize maximal benefit from medical therapy in post-myocardial infarction patients.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Judith M. MD, MS, Bradley MA, Kevin J. PhD, Donald MD, MBA, Richard MD, John P. MD, Barbara S. PA-C, MBA, Nancy Allen PharmD, Eric MD, MPH,